HLN Quote, Financials, Valuation and Earnings

GSK Plc has a net margin of 8.37% compared to Haleon Plc's net margin of 8.44%. Haleon Plc's return on equity of 8.91% beat GSK Plc's return on equity of 43.01%.

Haleon Plc has a consensus price target of $12.07, signalling upside risk potential of 21.78%. On the other hand GSK Plc has an analysts' consensus of $57.48 which suggests that it could grow by 1.39%. Given that Haleon Plc has higher upside potential than GSK Plc, analysts believe Haleon Plc is more attractive than GSK Plc.

Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.834%.

Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.86%. GSK Plc offers a yield of 3.11% to investors and pays a quarterly dividend of $0.49 per share. Haleon Plc pays 36.9% of its earnings as a dividend. GSK Plc pays out 47.15% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon Plc quarterly revenues are $3.5B, which are smaller than GSK Plc quarterly revenues of $11.5B. Haleon Plc's net income of $295.8M is lower than GSK Plc's net income of $966.8M. Notably, Haleon Plc's price-to-earnings ratio is 20.31x while GSK Plc's PE ratio is 15.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.07x versus 2.74x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.

Immunocore Holdings Plc has a net margin of 8.37% compared to Haleon Plc's net margin of -28.77%. Haleon Plc's return on equity of 8.91% beat Immunocore Holdings Plc's return on equity of -9.34%.

Haleon Plc has a consensus price target of $12.07, signalling upside risk potential of 21.78%. On the other hand Immunocore Holdings Plc has an analysts' consensus of $63.86 which suggests that it could grow by 107.13%. Given that Immunocore Holdings Plc has higher upside potential than Haleon Plc, analysts believe Immunocore Holdings Plc is more attractive than Haleon Plc.

Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immunocore Holdings Plc has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.946%.

Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.86%. Immunocore Holdings Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 36.9% of its earnings as a dividend. Immunocore Holdings Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon Plc quarterly revenues are $3.5B, which are larger than Immunocore Holdings Plc quarterly revenues of $104.3M. Haleon Plc's net income of $295.8M is higher than Immunocore Holdings Plc's net income of -$30M. Notably, Haleon Plc's price-to-earnings ratio is 20.31x while Immunocore Holdings Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.07x versus 3.97x for Immunocore Holdings Plc. Usually stocks with elevated PS ratios are considered overvalued.

Silence Therapeutics Plc has a net margin of 8.37% compared to Haleon Plc's net margin of -34617.65%. Haleon Plc's return on equity of 8.91% beat Silence Therapeutics Plc's return on equity of -94.26%.

Haleon Plc has a consensus price target of $12.07, signalling upside risk potential of 21.78%. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Haleon Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Haleon Plc is more attractive than Silence Therapeutics Plc.

Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.378%.

Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.86%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 36.9% of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon Plc quarterly revenues are $3.5B, which are larger than Silence Therapeutics Plc quarterly revenues of $34K. Haleon Plc's net income of $295.8M is higher than Silence Therapeutics Plc's net income of -$11.8M. Notably, Haleon Plc's price-to-earnings ratio is 20.31x while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.07x versus 506.96x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.